Offshore aquaculture has Trump’s backing, but that’s just the beginning – IntraFish

When it comes to unprecedented moments in seafood industry history, Mays executive order from President Donald Trump is certainly near the top.

The needs and desires of the US fishing and aquaculture sectors have traditionally not been the focus of Oval Office inhabitants, making Trumps May 6 proclamation a truly unique moment.

Its not uncommon for US presidents to use executive orders to unilaterally pursue policy objectives, but that doesnt lessen the significance or the potential of Trumps Promoting American Seafood Competitiveness and Economic Growth decree as far as its impact on the seafood industry, particularly the US aquaculture sector.

While the order seeks to streamline fisheries regulations and promote more fair seafood trade, much of the value of this executive order will be determined by whether the United States evolves into the aquaculture powerhouse it has been threatening to become for nearly 30 years.

The roots of the current executive orders aquaculture component can be traced back to 2005, when US Senate Commerce Committee Co-Chairmen Senators Ted Stevens of Alaska and Daniel Inouye of Hawaii introduced the National Offshore Aquaculture Act of 2005.

The bill, which became a template for future iterations of similar legislation, was developed by the National Oceanic and Atmospheric Administration (NOAA) and laid out a permitting process for offshore aquaculture development in US federal waters. It also encouraged investment and research in the sector.

The latest attempt to lift US aquaculture off the mat is a bill known as the Advancing the Quality and Understanding of American Aquaculture" (AQUAA) Act, which has been crawling its way through Congress since being first introduced in 2018. It seeks to establish an Office of Marine Aquaculture within NOAAs National Marine Fisheries Service to streamline aquaculture facilities permits, as well as help fund research and extension services for several existing aquaculture priorities.

A similar version was re-introduced in March by Representatives Steven Palazzo of Mississippi and Collin Peterson of Minnesota, chairman of the House Agriculture Committee. Expectations are a Senate version of the measure could be introduced this session.

The likelihood of any bills passage this session is low. The coronavirus pandemic and the upcoming presidential election have members of Congress focused elsewhere.

But the signing of the presidents executive order is likely to pump new muscle into the bill when the 117 th Congress convenes next January. It is impossible to know now whether Trump will still be president or whether a Democrat will rule the White House, and what impact that might have on the executive order and the bill. President Trump is noted for his repeal of many Obama-era executive orders.

Nevertheless, the executive order and the AQUAA Act are now intertwined and backed by bi-partisan and new environmental NGO support, giving it perhaps the best chance such a bill will ever have of becoming law.

Pushing a piece of legislation through Congress is one thing but getting the ear and the attention of the presidents advisors is something entirely different. During his confirmation hearing in January 2017 Commerce Secretary Wilbur Ross put a spotlight on the seafood industry, sending a signal that the White House was listening.

Given the enormity of our coastlines, given the enormity of our freshwater, I would like to try to figure out how we can become much more self-sufficient in fishing and perhaps even a net exporter," he said during the hearing.

A year later, Ross amplified this message during a budget hearing, saying the United States should be careful when importing seafood from countries that don't have similar aquaculture standards. He also said the United States could reduce the seafood trade deficit by pushing for maximum sustainable catch from its own fisheries, a message he continues to deliver.

With congressional willingness and a new receptive administration at the helm, all that was needed was a concerted industry push. It came in December of 2017 when leading executives from Sysco, Red Lobster, High Liner, feed-giant Cargill, Pacific Seafood, Taylor Shellfish and others formed the group Stronger America Through Seafood (SATS).

The group contracted with lobbyist Margaret Henderson -- who was vice president of government relations at the National Fisheries Institute (NFI) from 2005 to 2010 -- to help mount a political charge to address US aquaculture development.

The timing couldnt have been better. The Trump administration had released its 2018 -2022 strategic plan, which included a section on developing aquaculture in the United States.

A perfect storm was in the making, as the industry strengthened ties with the White House Office of Science and Technology Policy (OSTP) and the Presidents Office of Domestic Policy.

So where do we go from here?

While the executive order makes one mention of land-based fish farming in its definition of what aquaculture is, the proclamation is clearly focused on boosting offshore ventures. A bit ironic given the amount of money pouring into US land-based projects.

Nevertheless, the first step will be getting Congress to pass some version of the AQUAA Act and for the president to sign it.

With a November election hanging in the air, it is unknown whether Trump will still be president. If there is a change in the White House, it, too, is unclear whether the goals of the executive order will go forward with the new administration.

Nevertheless, the US aquaculture industry is closer than it has ever been to launching a new era of offshore fish farming, but yet it is still a long way away from this becoming a reality.

Any comments, complaints, retaliatory rants, please feel free to email me at: john.fiorillo@intrafish.com

See more here:

Offshore aquaculture has Trump's backing, but that's just the beginning - IntraFish

Cox & Kings created layers of onshore and offshore subsidiaries to siphon off money: ED – ThePrint

Text Size:A- A+

New Delhi: The Enforcement Directorate (ED) Monday conducted searches on the premises of the promoter, directors, CFO and auditor of the Cox & Kings Group (CKG) in Mumbai, which is allegedly involved in the Rs 3,642-crore Yes Bank fraud case.

Cox & Kings, the ED alleged, had created multiple layers of onshore and offshore subsidiaries across the globe, through which it siphoned off money.

The ED also alleged that the company forged its consolidated financials by falsifying the balance sheets of the overseas subsidiaries to get loans.

A formal complaint in this regard was filed on 18 March by Yes Bank, and during investigation irregularities were noticed in relation to the loan sanctioned to Cox & Kings Group.

The ED said in a statement that it searched premises of Ajay Ajit Peter, Pesi Patel, Abhishek Goenka, Anil Khandelwal and Naresh Jain, promoter/directors/CFO/auditor of Cox & Kings Group in Mumbai in Yes Bank fraud case of Rs 3642 crores under the provisions of Prevention of Money Laundering Act.

According to the ED, Cox & Kings Ltd (CKL), India, had an outstanding loan of Rs 563 crore, while Ezeego One Travel and Tours Ltd (EOTTL), India, had an outstanding of Rs 1,012 crore. Moreover, Cox & Kings Financial Services Ltd (CKFSL), India, had an outstanding loan of Rs 422 crore, Prometheon Enterprise Limited, UK, had an outstanding of Rs 1,152 crore and Malvern Travel Ltd, UK, of Rs 493 crore.

Also read: In Yes Bank crisis, you cant miss the ugly realities of Indias private sector lenders

According to the ED, Malvern Travel Limited, UK, an entity of CKG, had an outstanding of Rs 493 crore, which submitted the forged bank statement of RBS Bank, UK, State Bank of India, UK, and forged end-use certificates of BDO LLP (Statutory Auditor of the UK-based Entity) to avail the loan from Yes Bank.

According to the ED, this forgery was pointed out by KPMG, the administrator of this UK-based entity. It said the Bombay Stock Exchange and the National Stock Exchange were informed about this in writing.

The statutory auditor of the Prometheon Enterprise Limited, UK (PEL- a subsidiary of CKG) was Raffingers UK LLP, and the financials of PEL were sent to India by fictitious domain name impersonating the current officials of Raffingers UK LLP. For this, Raffingers UK LLP filed a criminal complaint to the National Crime Agency, UK, an ED official said.

According to the ED, after CKL defaulted on the loan, the lenders appointed PricewaterhouseCoopers for forensic audit, but the management did not cooperate.

However, based on the limited data available with them, PWC confirmed falsification of accounts, overstating the sales figures and understating the debt figures, fictitious transactions etc, a senior ED official said.

PWC reported that from FY15 to FY19, sales of Rs 3,908 crores were made to 15 non-existent, fictitious customers. Majority of collection shown in ledgers from Ezeego were not found in the bank statements, the senior official added.

According to the ED, the PWC report found another 147 sets of customers to be suspicious and non-existent.

Anil Khandelwal, CFO of CKL, diverted Rs 1,100 crore to Alok Industries Ltd without any approval of the board, the officer said.

The ED further claimed that CKG sold Holiday Break Education Limited, UK, another subsidiary for Rs 4,387 crore, and instead of discharging the liability of the bank, it siphoned off the majority of the money.

From this siphoning, USD 15.34 million was transferred to Kuber Investment Mauritius Pvt Ltd, which was controlled by Peter Kerker, the senior ED officer said.

From Ezeego, Rs 150 crore was diverted to Redkite Capital Private Limited, which was promoted by Khandelwal and Naresh Jain, internal auditor of CKL. This fund diverted to Redkite was used to buy a controlling stake in Tourism Finance Corporation Of India Ltd, a listed non-banking financial company, the officer added.

Also read: Yes Bank rescue is like Hotel California You can enter but cant exit

The ED registered a money laundering case against Yes Bank founder Rana Kapoor and others on 7 March on the basis of an FIR registered by the CBI.

In the FIR, it was alleged that between April and June 2018, Yes Bank had invested Rs 3,700 crore in the short-term debentures of Dewan Housing Finance Corporation Ltd (DHFL).

Simultaneously, Kapil Wadhawan, MD of DHFL, allegedly paid a kickback of Rs 600 crores to Rana Kapoor and his family members in the garb of loan given by DHFL to DOIT Urban Ventures (India) Pvt Ltd, also a Rana Kapoor Group Company.

In addition, the FIR said, Yes Bank Ltd also sanctioned a loan of Rs 750 crore to RKW Developers Group, which is beneficially owned by Kapil Wadhawan, Dheeraj Wadhawan and their family members. This loan was allegedly siphoned off by Wadhawans through their shell companies and it was never used for the declared purpose.

Investigation conducted under PMLA revealed the role of Rana Kapoor in money laundering and he, therefore, was arrested by the ED on 8 March, the ED said.

Also read: Moral of Yes Bank collapse story: Money makes you do things you dont want to

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

See the article here:

Cox & Kings created layers of onshore and offshore subsidiaries to siphon off money: ED - ThePrint

Remuneration To India Fund Manager Of Offshore Funds – Finance and Banking – India – Mondaq News Alerts

09 June 2020

NovoJuris Legal

To print this article, all you need is to be registered or login on Mondaq.com.

Pursuant tothe recent notification by the Central Board of Direct Taxes("CBDT"), there has been an amendment tothe income tax rules in relation tothe minimum remunerationpayable by an offshore fund to its India based fund manager("Fund Manager").

Income-TaxAct provides for a special taxation regime for certain eligibleinvestment funds, in the context of their fund managers beinglocated in India. To further encourage fund management from India,Section 9A of the Income-Tax Act, 1961, subject to otherconditions, was introduced to provide safe harbour rules whichfacilitated onshore management of offshore funds; thereby implyingthat, an offshore fund is not categorised as a resident in Indiasimply because its fund manager undertaking fund managementactivities on behalf of the offshore fund is located inIndia.

Previously,as a condition under the law, an offshore fund was required toensure that remuneration paid to the Fund Manager is not less thanthe arm's length price. This condition has been supersededafter April 1, 2019 and the remuneration thresholds have beenrevised to refine the provisions of the Act.The prevalentmethodology in relation to the minimum remuneration is tabulatedbelow:

OffshoreFund

Minimumremuneration payable to the Fund Manager

Category IForeign Portfolio Investor

atleast0.10%of the assets under management (i.e. theannual average of the monthly average of the opening and closingbalances of the value of such part of the fund which is managed bythe Fund Manager)

othereligible investment funds

i)0.3% of the assets under management; or

ii)10% of profits derived by such fund in excess ofthepre-defined threshold beyond which the fund agrees to paya share of the profits earned by the fund from the managementactivity undertaken by the Fund Manager (i.e the specified hurdlerate), where the remuneration is only income or profit linked;or

iii)50% of the management fee,attributable to the managementactivity undertaken by the Fund Manager, as reduced by the amountincurred towards operational expenses including distributionexpenses, if any.

However, incase the amount of remuneration is lower than the amount determinedas per the amended rules, the fund will be entitled to avail theopportunity to apply to the CBDT seeking approval for that loweramount to be the amount of remuneration. Upon receipt of suchapplication from the fund, the CBDT may, after considering therelevant facts, approve such lower amount as theremuneration.

Additionally,pursuant to the notification, the Fund Manager is also required toobtain a duly verified report from an accountant in the mannerspecified in Form No. 3CEJA, in respect of any activity undertakenby the Fund Manager for the fund. The report procured from anaccountant must certify that the fee received by the Fund Manageris in compliance with the prescribed rules.

Itmust be noted that the above regime is only applicable in relationto offshore funds which undertake fund management activities fromIndia and is not relevant in any other scenario.

Theincome-tax notification can be read here.

The content of this article is intended to provide a generalguide to the subject matter. Specialist advice should be soughtabout your specific circumstances.

POPULAR ARTICLES ON: Finance and Banking from India

Go here to read the rest:

Remuneration To India Fund Manager Of Offshore Funds - Finance and Banking - India - Mondaq News Alerts

Hermitage Offshore Becomes Latest to Issue "Going Concern" Warning – The Maritime Executive

Courtesy of Hermitage Offshore

By The Maritime Executive 06-05-2020 09:51:08

Hermitage Offshore Services became the latest company in the offshore sector to issue a dire financial outlook. The company said it has engaged financial advisors to provide consultation and has commenced discussions with its lenders.

The owner of 23 vessels consisting of 10 platform supply vessels, two anchor handling tug supply vessels, and 11 crew boats that primarily operate in the North Sea or the West Coast of Africa, said that current circumstances give rise to substantial doubt about the companys ability to continue as a going concern.

In reporting first quarter results, the company cited the outbreak of COVID-19 coupled with the abrupt deterioration in the price of crude oil resulting, which prompted significant reductions of both current and planned capital expenditure outlays from major oil producers throughout the world. Consequently, it said, the markets in which the company's vessels operate, particularly in the North Sea, have come under significant pressure in the form of reduced spot market rates and utilization, higher lay-up activity, and contract cancellations and renegotiations.

Hermitage became just the latest company in parts of the offshore sector to raise concerns. At the beginning of the week, offshore rig operator Seadrill said that it would voluntarily delist from the New York Stock Exchange followed by issuing its own going concernwarning for investors, citing the fundamental market imbalance between rig supply and demand.

Numerous companies related to the offshore industry have also announced cutbacks in their workforces. Subsea 7 announced this week that it would reduce its headcount by about 3,000 employees during the second quarter out of a global workforce of 12,000. In the North Sea, Maersk Drilling announced about 300 layoffs in April and another 150 in May. In the U.S. Gulf of Mexico oil patch, the Louisiana Oil & Gas Association indicates that its members have already laid off as much as a quarter of its workforce.

Siem Offshore, which operates a fleet of 35 vessels serving the oil and gas industry, announced in April that it has entered into a standstill agreement with its secured lenders in Europe and Norway as a first step toward improving cash flow and liquidity to maintain operations. Siem, however, must also obtain a similar agreement with its secured lenders in Brazil and Canada as well as obtaining approval from its bondholders to defer payments and suspend their acceleration rights.

After years of struggling with oversupply and weak demand, many analysts point to the challenges in the current economic downturn from the global pandemic as causing the current collapse in the industry.

See the original post:

Hermitage Offshore Becomes Latest to Issue "Going Concern" Warning - The Maritime Executive

Miclyn Express Offshore Awarded Long-Term Charter In Thailand For 14 Crew Boats – Hellenic Shipping News Worldwide

Miclyn Express Offshore has contracted 14 of their crew boats on a long term charter with a leading E&P company in Thailand for 1,095 days from May 2020. This fleet of crew boats will support oil & gas production activity via inter-field transfer of personnel and cargo, evacuation and emergency response operations. The fleet service a significant number of platforms that form part of multiple oil & gas production fields within the Gulf of Thailand and operate on a very economic fuel consumption model to minimize operating costs for the charterer.

Created with RNI Films app. Preset Technicolor 2 HC

The project was contracted through Uniwise Offshore Ltd, a joint-venture between the Singapore headquartered, Miclyn Express Offshore and their local shipyard and logistics partner, Unithai Group. The management of these crew boats are carried out from the shore support bases in Songkhla and Sattahip. Uniwise has served this client with good track record for 20 years. Established in 1999, the joint-venture manages over 25 vessels in Thailand.Source: Miclyn Express Offshore

Read this article:

Miclyn Express Offshore Awarded Long-Term Charter In Thailand For 14 Crew Boats - Hellenic Shipping News Worldwide

In the midst of coronavirus crisis lies great opportunity for Canadas offshore oil and gas industry – The Conversation CA

Newfoundland and Labradors offshore oil and gas industry is facing major challenges due to plummeting oil prices and the COVID-19 pandemic. Exploration wells have been postponed and several large projects have been deferred.

Albert Einstein once said, In the midst of every crisis, lies great opportunity. With the vast resources, infrastructure, highly skilled individuals and expertise of the offshore industry, Canada has a unique opportunity to be a global leader in the transition to alternative and new offshore energy technologies.

As dean of the faculty of engineering and applied science at Memorial University, I see the bright potential of recent graduates and talented young minds. They have the ability and desire to create innovative solutions to the worlds energy challenges.

To realize this vision at a time of crisis in the offshore industry, Canada needs to step up by offering its support, such as through the Atlantic Investment Tax Credit or another similar program, to get offshore projects moving again. Canada also needs to expedite the approval of new projects.

The offshore oil and gas industry has significantly contributed to Memorial University; professors and their research programs; students through scholarships and bursaries; and more broadly, the province of Newfoundland and Labrador with employment opportunities, among others.

Co-operative education has enabled our students to gain valuable industry experience prior to graduation. Typically at least one-third of engineering co-op placements have been related to the oil and gas sector, or over 400 work terms each year.

Read more: New Hebron offshore oil platform a Canadian engineering marvel

In recent years, the proportion has been up to nearly half of all co-op work terms. Peaks have occurred during periods of local major construction projects in the industry, such as White Rose, Hebron and the more recent West White Rose expansion project.

For four years in a row, Newfoundland and Labrador had the highest percentage of women undergraduate engineering students in Canada (27 per cent). Quality coop work term experiences in the oil and gas industry have been important factors in attracting and retaining women in engineering.

These opportunities cover a diverse range of valuable learning experiences. Students have worked in many areas such as with operators, service providers to operations, construction, exploration, certification, regulation, research and development, and local startup companies connected with the offshore industry.

Beyond energy alone, petrochemicals also have much broader importance in society and applications such as polymers in personal protective equipment (PPE) for the current battle against COVID-19.

Climate change is one of the worlds largest and most difficult problems. I believe that great universities like Memorial solve the worlds greatest problems. Also the oil and gas industry has an important role as it creates highly skilled jobs and advanced energy technologies that are needed to solve the grand challenge.

More research and development involving graduate students will be essential. The offshore industrys support of these programs and students has contributed to a more responsible development of offshore oil resources.

Environmentally conscious projects have been made possible through support of the oil and gas industry. These include, but are not limited to, projects that are developing new technologies for carbon capture, wind-powered thermal energy storage and alternative fuels like hydrogen, among others.

Read more: Biden, Keystone XL and a Green New Deal could shake up Canada's energy industry

Researchers have been able to leverage this support for additional funds through other federal granting agencies to expand the research and development on sustainable energy solutions.

Earlier in my career, I was a Canada Research Chair in Advanced Energy Systems. Past oil industry support helped me to secure funding to develop new processes for clean hydrogen production (solar photo-electrochemical and thermochemical copper-chlorine cycle) in collaboration with the Canadian Nuclear Laboratories (formerly Atomic Energy of Canada Ltd.) in Chalk River, Ont.

These processes can enable future power plants to produce both electricity and hydrogen as clean energy carriers. Hydrogen is potentially a major solution to climate change.

A recent report by an industry coalition including Chevron and Shell indicated that hydrogen energy has the potential to generate 700,000 jobs and US$140 billion per year of revenue in the United States alone by 2030 and up to 3.4 million new jobs and US$750 billion per year by 2050.

The oil and gas sector has transformed Newfoundland and Labrador and its standard of living in a positive way over the past few decades. It has enabled the province to provide better quality education, health care and jobs, among many others.

Supporting Canadas offshore industry would yield a lower overall carbon footprint than importing foreign oil to meet domestic demand because of our higher environmental standards and policies of putting a price on pollution.

The Newfoundland and Labrador Oil and Gas Industries Association (NOIA) supports Canadas efforts to achieve net-zero emissions by 2050. As reported by NOIA, Canadas offshore industry produced just 0.23 per cent of the countrys upstream carbon emissions in 2017.

Equinor (formerly Statoil) is active in exploration and development in offshore Newfoundland. As an energy company, it expanded into renewable energy and began operations on the worlds largest floating wind farm in 2017, off the coast of Scotland. Equinors prior experience with offshore oil reservoirs was important to be able to open up deep-water areas for power development.

Newfoundland and Labradors offshore sector and spinoffs from the industry are critically important to the economy. Canada needs to support this industry during its time of greatest need. We can then look back years from now to see how opportunities of new energy innovations were seized from the depths of a global crisis.

View post:

In the midst of coronavirus crisis lies great opportunity for Canadas offshore oil and gas industry - The Conversation CA

Storms everywhere for the offshore industry – WorkBoat

As Tropical Storm Cristobal heads toward the U.S. Gulf Coast, sending offshore workers and equipment scurrying out of its way, it isnt the only storm endangering the offshore energy business.

Debt and a fall off in activity are decimating company cash flows and balance sheets. Without cash flow, solving the debt issue becomes impossible without significant financial restructuring.

While managements would love to renegotiate their loan and bond indentures with lenders in private, most of the action will be done under bankruptcy protection. The outcome will be companies with new owners, as debt is swapped for equity, leaving current shareholders with little or no value. New company directors, and often new management, are also part of the restructuring process. The former debt-holders, and now new shareholders, are driven by one goal recapture as much of their loan value through improved share prices and/or sale of equipment. For them, it becomes a race to see how quickly the industrys and companys fortunes improve, and the holders desire to generate cash returns.

A recent presentation by Rystad Energy analysts offered a sobering outlook for the floating rig segment of offshore drilling, and implicitly the entire business. Their view of the industrys future was supported by comments from Seadrill chief executive Anton Dibowitz earlier this week during the companys first quarter earnings call. He summarized the problems facing Seadrill and all offshore drillers: This industry has two fundamental challenges which are emphasized by recent events there are too many rigs carrying too much debt a number of our assets are increasingly unlikely to return to the market and need to be scrapped. Assets across the industry also carry debt levels which are unlikely to be sustainable and consequently we should expect to see substantial indebtedness being converted into equity.

This problem was identified by Rystad. It showed that beginning in 2015, following the 2014 oil price drop, E&P companies exploration spending no longer tracked their cash flow, a first for the industry. As exploration and greenfield development spending accounts for 38% and 39%, respectively, of spending on floating drilling rigs, the change in E&P company philosophies for managing their long-term future has cut in half the market for these rigs.

Rystad calculated that the ratio of customers to floater companies is now one-to-one. As a result, drilling contractor pricing leverage doesnt exist, jeopardizing future rig utilization and earnings. Without cash flow, debt restructurings will follow. Longer term, this will drive industry consolidation. Rystad says the floater industry went from 15 to 11 contractors following the acquisitions by Transocean and Valaris. It now says the industry may be headed to only four contractors. If correct, theres a hurricanes worth of pain and suffering ahead for the industry, something it cant avoid.

See the original post here:

Storms everywhere for the offshore industry - WorkBoat

Comet of the Week: PANSTARRS C/2017 K2 – RocketSTEM

LEFT: Pre-discovery image of Comet PANSTARRS taken with the Canada-France-Hawaii Telescope at Mauna Kea on May 12, 2013, when its heliocentric distance was 23.7 AU. From the paper by Jewitt et al. (2017). RIGHT: Hubble Space Telescope image of Comet PANSTARRS taken on June 27, 2017, when its heliocentric distance was 15.9 AU. Courtesy NASA.Perihelion: 2022 December 19.67, q = 1.797 AU

Ive hinted in some of the earlier presentations of Ice and Stone 2020 that, for the past few years, we have been in a slow period when it comes to bright comets. Indeed, for Great Comets discussed in a previous Special Topics presentation the most recent one appeared in 2011, and the most recent one that was easily visible from the northern hemisphere appeared as long ago as 1997. Weve been teased a couple of times in the very recent past, but Comet ATLAS C/2019 Y4 (an earlier Comet of the Week) disintegrated as it approached perihelion, and while it was never expected to become Great, Comet SWAN C/2020 F8 (discussed in that same presentation) apparently did likewise. So far, Comet NEOWISE C/2020 F3 seems to be brightening normally, but well have to wait and see what happens next month.

Intrinsically, this weeks Comet of the Week is one of the brightest ever detected its intrinsic brightness being comparable to that of Comet Hale-Bopp C/1995 O1 and while it certainly possesses the potential to become a bright, perhaps even conspicuous, naked-eye object around the time of its perihelion passage, its somewhat large perihelion distance, combined with the fact that it remains far from Earth and will be visible only under mediocre viewing geometry, will likely keep it from becoming Great. Furthermore, since it will be accessible only from the southern hemisphere for almost a full year around the time of perihelion, as far as observers in the northern hemisphere are concerned any potential it might have for becoming conspicuous is quite limited.

At the time of its discovery by the Pan-STARRS program based in Hawaii on May 21, 2017, the comet was about magnitude 19.5, and despite being located at a heliocentric distance of 16.1 AU was already clearly active. Researchers later identified images of it on exposures taken with the Canada-France-Hawaii Telescope at Mauna Kea as far back as May 12, 2013, at which time it was located 23.7 AU from the sun the second-largest heliocentric distance at which any long-period comet has ever been detected; it was about magnitude 22.5 but was still showing activity even at that distance. Since this is far too large a distance for the sublimation of water ice, researchers have concluded that the activity was driven by sublimation of substances like carbon dioxide, carbon monoxide, and molecular oxygen and nitrogen.

Traveling in an orbit almost perpendicular to the ecliptic (inclination 87.5 degrees), Comet PANSTARRS has brightened steadily ever since its discovery as it has approached the inner solar system, and presently is around 15th to 16th magnitude. It is currently at opposition at a heliocentric distance of 8.9 AU, and located within the head of the constellation Draco. It travels slowly southward over the coming months, and will be in conjunction with the sun 59 degrees north of it in mid-December. A year from now it is again at opposition, when its heliocentric distance will be 6.1 AU and it will be located 10 degrees south of its current location; by then it may be close to 13th magnitude and thus amenable to visual observations. One year later, i.e., in mid-June 2022, it will once again be near opposition, at a heliocentric distance of 2.9 AU and located in northern Ophiuchus; by then it should be bright enough to detect with binoculars and perhaps may even be close to naked-eye visibility.

After this, Comet PANSTARRS travels southward more rapidly, becoming inaccessible from northern temperate latitudes by the end of September and entering southern circumpolar skies in mid-December. At the time of perihelion is in conjunction with the sun 38 degrees south of it and is located on the far side of the sun from Earth. It reaches a peak southerly declination of -71 degrees shortly before the end of January 2023, and is still in southern circumpolar skies when it is nearest Earth (2.23 AU) in mid-February. Although it continues traveling northward it remains at a relatively small elongation south of the sun for the next several months, and is again in conjunction with the sun 37 degrees south of it in mid-June. During August it emerges into the morning sky and once again becomes accessible from the northern hemisphere, and will be at opposition shortly after mid-December when it will be located a few degrees east of the Orion Nebula M42; during the first few days of January 2024 it travels northwestward parallel to the stars of Orions Belt about 1 degrees south of that prominent stellar pattern. Visual observations may be possible for a few more months as it travels northward through the western evening sky and fades as it recedes from the earth and sun.

As is always the case with inbound long-period comets, any forecasts as to its brightness should be taken cautiously. The comet appears to be a new one making its first visit to the inner solar system from the Oort Cloud, and as discussed in a previous Special Topics presentation such objects tend to under-perform compared to what their earlier brightnesses might suggest. The fact that Comet PANSTARRS appears to be quite bright intrinsically and was active at such large heliocentric distances works in its favor, but its rather large perihelion distance, its remaining far from Earth, and its poor geometric viewing conditions around the time of perihelion work against it. The comet should certainly reach naked-eye brightness, perhaps 5th magnitude, and could become somewhat brighter than that; 3rd magnitude perhaps is reasonable, and while I would consider a peak brightness of 1st magnitude as unlikely, it is not out of the question. As I stated at the outset, though, I doubt that this will become a Great Comet, although I suppose one never knows. We will just have to wait and see what the comet does.

This Week in History Special Topic Free PDF Download Glossary

View original post here:

Comet of the Week: PANSTARRS C/2017 K2 - RocketSTEM

Comet me, bro: A giant asteroid will pass relatively close to Earth – The New Daily

An asteroid the size of a stadium is set to pass relatively close to Earth on Saturday.

If there was any catastrophic event we were missing in 2020, its a giant asteroid hurtling towards us.

NASA has advised that while the 335-metre mass is near enough to make their close approach list, it will still miss us by a landslide about 5.1 million kilometres to be exact.

The asteroid, named 2002 NN4 (the runner-up in Elon Musk and Grimes baby name list), is said to be bigger than 90 per cent of asteroids and could have devastating effects if it entered Earths orbit.

But we can breathe a sigh of relief, because despite travelling at more than 32,000 kilometres per hour, 2002 NN4 will still be more than 13 times further away from us than the Moon.

Ian J. ONeill, of NASAs Jet Propulsion Laboratory, said the asteroid was too far away to worry.

In short, 2002 NN4 is a very well-known asteroid with a known orbit that will pass Earth at a (very) safe distance Dr ONeill said.

Along with 2002 NN4, there are another four asteroids on their way over, but they are significantly smaller.

One is roughly the size of a house while the remaining three are the size of an aeroplane.

NASA has also blessed star-gazers with an Asteroid Watch Widget, which tracks asteroids and comets as they approach Earth.

Users will be able to find out the date of the closest approach, name and size of the asteroid and its distance from Earth.

Despite fitting in well with the chaos this year has brought, 2002 NN4 will be so far away sky-gazers will still need a telescope to see it.

But what would happen if it came any closer?

Scientists from all over the world met in 2019 to discuss how to respond if a disastrously large asteroid actually was headed for Earth.

Dr Lori Glaze, director of planetary science at NASA, said that literally saving the world wouldnt be too hard.

All we have to do is change its speed a little faster or a little slower so that when it crosses Earths orbit, it crosses either in front of us or behind us, Dr Glaze said.

Excerpt from:

Comet me, bro: A giant asteroid will pass relatively close to Earth - The New Daily

Carol Schram – Utica Comets year-end award winners will help fill out Canucks’ Black Aces – Hockeybuzz.com

Last week, the Vancouver Canucks' AHL farm team rolled out its team awards for 2019-20.

Leading scorer Reid Boucher picked up three awards named MVP by both the team and the local media, as well as winning the Three Stars Award.

Goaltender Mikey DiPietro was named 'Class Guy' and 'Guy With The Most Heart':

Guillaume Brisebois earned the award for best defenseman:

Sophomore Kole Lind was named the team's most improved player.

And team captain Carter Bancks was named Best in the Community.

Some players from that group will be joining the Canucks when their training camp gets underway in Phase 3 of the Return To Play Plan, likely in July as things look now.

Back in May, we started discussing which Utica Comets players could earn the call to be Black Aces when the Canucks get back in action.

Iain MacIntyre of Sportsnet took on that subject on Monday.

He emphasizes once again that we don't know if Micheal Ferland or Josh Leivo will be ready to play when camp gets underway but regardless, the big club already has a surplus of forwards.

We have five lines of forwards (at the NHL level), so we dont have to bring in as many forwards," Canucks general manager Jim Benning told MacIntyre. "But weve only got seven D, so if you have two guys go down, the second injury on defence, one of those guys called up is going to play."

I've read that total roster size is still something that needs to be finalized in the Phase 3 protocol. Using the parameter of 28 skaters that has been widely circulated, MacIntyre figures probably two forwards and three defensemen, plus DiPietro, will get the nod from the group of "10 or 11" players who were told to stay ready after the AHL season was officially cancelled last month.

For his part, Travis Green left little doubt that he's looking for a roster that'll give his team the best chance to win and advance.

People say, Youll finally play meaningful games, Green told MacIntyre. Thats not what this is about to me. Its not about getting a few games under our belt under hard and exciting circumstances, in pressure-filled games. This is about, how do we win the first series, and then how do we win the second series? And I can tell you, were not going into this thinking were only going to be playing one or two rounds.

As MacIntyre points out, that mindset probably gives the edge to players with experience.

After factoring in team needs, he namechecks Brogan Rafferty, Guillaume Brisebois and Olli Juolevi as the likely candidates on defense, along with Tyler Graovac and Reid Boucher up front.

Based on the experience theory, I'd probably put Ashton Sautner ahead of Juolevi as a left-side blueliner. And despite another stellar AHL season from Boucher, I wonder if the Canucks would be more tempted to tap Sven Baertschi, who stayed healthy all season and whose skating is more NHL-ready?

Baertschi's 27, has 291 games of NHL experience, and has 138 points 0.47 points per game.

Boucher's a year younger at 27, has 133 games of NHL experience, and has 42 points 0.32 points per game.

Also even if the first priority is to try to win some hockey games, Benning might get an additional benefit from putting Baertschi into the lineup. If he does well especially on such a big stage perhaps that opens the door for Benning to deal the last year of Baertschi's contract, something he wasn't able to do at the trade deadline in February.

It'll be interesting to see how these decisions play out once an official date for the start of training camp is set and roster sizes are finalized.

To close out today this one's for all you foodies. The NHL is launching a new cooking show this week.

'Skates & Plates' debuts this Wednesday, with one-time Vancouver Canucks centre Nick Bonino learning how to make the classic French dish Steak Diane and pommes frites from celebrity chef Ludo Lefebvre.

I've seen the episode it's a lot of fun. Bonino's great, and the meal looks amazing.

I wrote about it for Forbes. Read the story and check out the trailer here. Thanks!

Read the original here:

Carol Schram - Utica Comets year-end award winners will help fill out Canucks' Black Aces - Hockeybuzz.com

Molecular Medicine Research – Department of Molecular …

The Department of Molecular Medicine is actively engaged in research and education to build a premier virus, gene and cell therapy program and to translate promising therapeutics from bench to bedside in a timely manner.

The wide range of disciplines represented the Department of Molecular Medicine's leadership team and staff facilitates a breadth of translational activities. The researchers in the Department of Molecular Medicine are in the unique position of being able to move a basic science discovery all the way through to clinical trials and the development of novel therapies, all within the department and in an expedited fashion. For instance, instead of the standard five- to seven-year industry time frame, the department has moved their attenuated measles virus therapy for ovarian cancer from discovery to clinical trials within three years. This integrated process enables the advancement of science and the quick delivery of new treatments to patients.

Researchers from the Department of Molecular Medicine participate in achieving the center's goal of personalizing each person's treatment for optimal care. The Molecular Medicine department's research team is focused on advancing the center's research into biomarker discovery. Researchers are also actively involved in applying their expertise in gene therapy to the field of regenerative medicine, particularly in the areas of beta cell regeneration and liver regeneration.

The Department of Molecular Medicine works with the Gene and Virus Therapy Program of the Mayo Clinic Cancer Center Research to develop new gene delivery systems and gene and virus-based therapies for cancer treatment. The program conducts research on all Mayo Clinic campuses. The Gene and Virus Therapy Program focuses on four areas of research:

Core facilities such as the Viral Vector Production Laboratory and the Toxicology and Pharmacology Shared Resource manufacture clinical-grade engineered viruses and perform preclinical toxicology and biodistribution studies to support the department's clinical trials.

Read this article:

Molecular Medicine Research - Department of Molecular ...

Explainer: What are antibody therapies and who is developing them for COVID-19? – Reuters

NEW YORK (Reuters) - While some potential vaccines have emerged in the global race to find a way to stop the spread of COVID-19, many scientists and researchers believe antibody based therapies hold great promise for treating people already infected with the disease.

FILE PHOTO: An apheresis machine separates and collects convalescent plasma from the whole blood of a recovered coronavirus (COVID-19) patient at the Central Seattle Donor Center of Bloodworks Northwest during the outbreak in Seattle, Washington, U.S. April 17, 2020. The plasma from recovered patients will be used in an experimental treatment study for current coronavirus patients. REUTERS/Lindsey Wasson

These therapies use antibodies generated by infected humans or animals to fight off the disease in patients. They date back to the late 19th century, when researchers used a serum derived from the blood of infected animals to treat diphtheria.

For COVID-19 treatment, researchers are studying the use of convalescent plasma and other treatments made with blood from recently recovered patients.

More recently, scientists have developed treatments called monoclonal antibodies antibodies that can be isolated and manufactured in large quantities to treat diseases like Ebola or cancer. Companies, like Eli Lilly and Co (LLY.N) and Regeneron Pharmaceuticals (REGN.O) in the United States, are trying to use this approach to develop their treatments.

Unlike convalescent plasma, manufacturers do not need a steady supply of antibody-rich blood to produce monoclonal antibodies, so this approach could be easier to scale up.

In general, the goal of a vaccine is to generate an immune response that can prevent someone from getting ill with a disease, whereas antibody-derived products are generally designed to treat disease.

And while some drugmakers have suggested antibody treatments can be used prophylactically - Regenerons Chief Scientific Officer George Yancopoulos has said their treatment could be a bridge to a vaccine - it could be expensive.

You might go into nursing homes or the military and use it because antibodies have a pretty long half life, said Dr. Betty Diamond, Director of Molecular Medicine at the Feinstein Institutes for Medical Research.

You might decide that you are going to use this as a prevention in this very high risk group, but you wouldnt do that for the whole country.

The amount of protein in antibody drugs makes the treatment more expensive than vaccines in general, Feng Hui, chief operating officer at Shanghai Junshi Biosciences (1877.HK), said.

Designing antibody drugs to treat or protect high risk people, including those with weak immune systems, could require hundreds, or even over a thousand times more protein than found in a vaccine shot, according to Junshi.

WHO IS DEVELOPING ANTIBODY THERAPIES FOR COVID-19?

Eli Lilly is collaborating with Junshi and Canadian biotech firm AbCellera Biologics to develop different antibody treatments, both of which have started early stage testing in humans.

Regeneron plans to start clinical studies later this month to test its antibody cocktail treatment, which was derived from antibodies from genetically-modified mice. It aims to have hundreds of thousands of preventative doses available by the end of the summer or the fall.

The CoVIg-19 Plasma Alliance, which includes Japans Takeda Pharmaceuticals (4502.T) and CSL Behring, is working on hyperimmune globulin therapy derived from convalescent plasma, which could offer a standardized dose of antibodies and doesnt need to be limited to patients with matching blood types.

The Antibody Therapy Against Coronavirus (ATAC) project, funded by the European Commission and led by Swedens Karolinska research institute, is looking at a similar approach as well as monoclonal antibodies. Under the project, monoclonal antibodies extracted from convalescent plasma are now being tested on human volunteers in Germany and on animals in Switzerland.

Britains GlaxoSmithKline (GSK.L) is working with Vir Biotechnology Inc (VIR.O) to develop potential antibody treatments which select the best antibodies out of the plasma.

AbbVie (ABBV.N) has also announced a collaboration to develop antibody therapies.

Singapores state research body A*Star is working with Japans Chugai Pharmabody Research on an antibody for clinical use.

Reporting by Michael Erman; Additional reporting by Francesco Guarascio in Brussels, Roxanne Liu in Beijing and John Geddie in Singapore; Editing by Miyoung Kim & Simon Cameron-Moore

Originally posted here:

Explainer: What are antibody therapies and who is developing them for COVID-19? - Reuters

Medicine in the time of corona: Fundamental molecular research is essential – Science Advances

Ali Shilatifard

A pandemicespecially one caused by a mysterious or newly discovered infectious agentengenders a stark reminder that supporting fundamental research has been a prudent investment of public funds. Fundamental molecular research plays an essential role in the clinic to decipher infectious processes, develop therapeutic strategies, and guide physicians, nurses, and other hospital employees in implementing the most effective application of new knowledge. As the world begins the process of healing from the medical, social, and economic effects of coronavirus disease 2019 (COVID-19), public health is at the forefront of decision-making by lawmakers at both the federal and state levels. Daily news conferences and press releases illustrate the importance of scientists and physicians as major partners in pandemic task forces, guiding politicians in health policy decision-making. Basic molecular research plays a crucial role in helping the world overcome the current pandemic and prepare for the next one.

The first application of fundamental molecular research to COVID-19 was rapid sequencing of the SARS-CoV-2 RNA genome using a process known as next-generation sequencing (NGS). These data immediately delivered the scientific and clinical communities with insight into the singular properties of this coronavirus strain. NGS can provide billions of DNA reads in a single day, a process that was unfathomable only 15 years ago. Now an essential and nearly ubiquitous technology, NGS evolved through the research of biochemists, molecular biologists, and engineers who were supported by grants from publicly funded institutions such as the U.S. National Institutes of Health (NIH), National Cancer Institute (NCI), and their counterparts across the globe. The second major application of fundamental molecular research to COVID-19 was the development of an assay to identify infected individuals. The method of choice for high-sensitivity detection of the virus in people is reverse transcription followed by polymerase chain reaction (RT-PCR), which takes advantage of the viral genome sequence provided by NGS. A key component of this assay is the reverse transcriptase RNA-dependent DNA polymerase, which converts the viral RNA genome into a DNA molecule that can be amplified and detected. This enzyme was a Nobel prize winning discovery by NIH/NCI-supported researchers Howard Temin and David Baltimore. Although the PCR amplification methods and instruments were finalized in the private sector, much of the enzymology and nucleic acid chemistry that spurred PCR development was based on publicly funded fundamental molecular research.

Developing COVID-19 therapeutics requires an in-depth understanding of molecular processes involved in the viral life cycle. Antiviral therapies are needed to treat patients with mild to moderate symptoms. Additional therapies are needed for COVID-19 patients who suffer cytokine storm, which progresses to critical stages of respiratory failure, septic shock, and multiorgan dysfunction. Given that COVID-19 is within the family of RNA viruses, researchers are well positioned to begin development of antiviral therapies, as biochemists already have generated a plethora of molecular information about the atomic structures for the main enzyme required for viral replication, the RNA-dependent RNA polymerase, an enzyme which has no known host counterpart. In this case, biochemists and transcription biologists have already identified Remdesivir, an adenosine nucleotide analog that interferes with the action of viral RNA-dependent RNA polymerase activity. Clinical trials of the drug are currently underway, and early results are encouraging. As for the treatment of cytokine storm, again, basic biochemical research in immunology has paved the way for the development of several therapies, including interleukin-6 (IL-6) inhibitors that function by blocking the IL-6 receptor and ameliorate unwanted damage to tissues and organs caused by cytokine release as the result of viral infection.

The ultimate aim for the treatment of all viral infections, including COVID-19, is the development of host and herd immunity, which can be accomplished either through host infection or vaccination. To manage potential pandemics with the least number of casualties, researchers must develop vaccines that can be mass produced on a scale of hundreds of millions of doses within in a few months after a virus appears and that can be rapidly distributed across the globe. Traditional vaccines use either active or weakened virus or destroyed forms of viral particles as the immune responsegenerating agent. The use of attenuated and destroyed viral particles as vaccines is highly effective, but the manufacturing process is arduous and time-consuming. Recombinant RNA and DNA vaccines circumvent these shortcomings of traditional vaccine generation and are in clinical trial for COVID-19. In this case, humankind owes biochemists Paul Berg, Walter Gilbert, Frederick Sanger, and their colleagues a debt of gratitude for their Nobel prize winning fundamental research in developing recombinant DNA technologies. This work resulted from decades-long funding by U.S. and U.K. governmental agencies and, today, allows the design of recombinant RNA and DNA vaccines and many other life-saving medicines that take advantage of this revolutionary technology.

Once the dust from the COVID-19 pandemic settles and the U.S. Congress is back in session, I hope that lawmakers will recognize our societys dependence on thorough, methodical, mechanistic science and the medicines it provides and ask themselves how many more people might have perished from COVID-19 without the modern methods that arose from the basic molecular research described above. This catastrophe should be a reminder that a healthy investment in all institutes of the NIH and NCI and other federal science agencies will be life-saving when future pandemics arise.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Read the original here:

Medicine in the time of corona: Fundamental molecular research is essential - Science Advances

Reminder – BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical…

Westport, CT, June 08, 2020 (GLOBE NEWSWIRE) --

BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced a reminder that it will host a call to discuss the Phase II clinical trials of merimepodib, its broad-spectrum oral anti-viral candidate for the treatment of COVID-19 in adult patients.

The format will be a management presentation updating recent developments followed by a Q&A session with select call attendees.

Conference Call Details:

Date: Tuesday, June 9, 2020Time: 11:00 AM Eastern Time (ET)Dial in Number for U.S. Callers: 1-877-407-8293Dial in Number for International Callers: 1-201-689-8349

A replay will be available for two weeks starting on June 9, 2020 at approximately 2:00 PM ET. To access the replay, please dial 1-877-660-6853 in the U.S. and 1-201-612-7415 for international callers. The conference ID# is 13704617.

On May 14, 2020, an article titled, "The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro" was published by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine. The article cites that merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing.

On May 18, 2020, ViralClear announced the FDAs clearance of its IND to proceed with a proposed Phase II study of merimepodib in COVID-19 patients. The human clinical trial is planned to be conducted under the leadership of Dr. Andrew D. Badley, Professor and Chair of the Department of Molecular Medicine and the Enterprise Chair of the COVID-19 Task Force at Mayo Clinic.

On June 5, 2020, ViralClear announced that it has expanded its patient enrollment centers to include St. Davids South Austin Medical Center in Austin, TX. The hospital is part of St. Davids HealthCare, one of the largest healthcare systems in Texas. The Company intends to commence its Phase II clinical trial for merimepodib, its broad-spectrum oral anti-viral candidate for the treatment of COVID-19 in adult patients in the coming weeks.

About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Companys first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About Viral Clear Pharmaceuticals and Merimepodib (MMPD)BioSigssubsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed. A manuscript titled, The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro, was submitted to an online peer-reviewed life sciences journal. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (ViralClear) as a corresponding author. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.

Forward-looking StatementsThis press release contains forward-looking statements. Such statements may be preceded by the words intends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Companys control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Companys filings with the Securities and Exchange Commission (SEC), including the Companys Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SECs website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

More here:

Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical...

Targeting Receptor EphA2 Reduces Bladder Cancer Tumor Growth and Increases Chemotherapy Effectiveness – Newswise

An international team of investigators has recently discovered that the receptor tyrosine-kinase EphA2 activated by the growth factor progranulin is a tumorigenic driver of bladder cancer progression.

The study, Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer, has been recently published in the international-peer-reviewed journal Matrix Biology. The paper describes how EphA2 depletion severely blunted progranulin-dependent motility and anchorage-independent growth, and sensitized bladder cancer cells to cisplatin treatment.

The authors, including Dr. Andrea Morrione, currently at the Sbarro Institute for Cancer Research and Molecular Medicine, and the Center for Biotechnology at Temple University, Dr. Renato V. Iozzo from the Department of Pathology, Anatomy and Cell Biology at Thomas Jefferson University, and Dr. Antonino Belfiore from the University of Catania, Italy, had previously demonstrated that the growth factor progranulin plays a critical role in bladder cancer by modulating tumor cell motility and invasion, and discovered that progranulin targeting markedly reduces in vivo tumor growth and sensitizes urothelial cancer cells to cisplatin treatment. The authors recently identified EphA2, a member of a large family of receptor tyrosine-kinases, as the functional receptor for progranulin. However, It was not previously established whether EphA2 plays an oncogenic role in bladder cancer.

This study demonstrates that progranulin is the predominant EphA2 ligand in bladder cancer. Progranulin evokes Akt- and Erk1/2-mediated EphA2 phosphorylation at Ser897, which could drive bladder tumorigenesis. They further defined the mechanisms of progranulin/EphA2-dependent motility by identifying liprin-1 as a novel progranulin-dependent EphA2 interacting protein and establishing its critical role in cell motility.

As stated by Dr. Antonio Giordano, Founder and Director of the Sbarro Health Research Organization at Temple University, the discovery of EphA2 as the functional signaling receptor for progranulin and the identification of novel downstream effectors offers a new avenue for understanding the underlying mechanism of progranulin action, and may constitute novel clinical and therapeutic targets in bladder cancer.

Bladder cancer is one of the most common and aggressive cancers worldwide and, regardless of the treatment, often recurs and spreads to surrounding tissues. Thus, a deeper knowledge of the mechanisms driving bladder tumorigenesis is critical for novel rational therapeutic strategies.

About the Sbarro Health Research OrganizationThe Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visitwww.shro.org

See the article here:

Targeting Receptor EphA2 Reduces Bladder Cancer Tumor Growth and Increases Chemotherapy Effectiveness - Newswise

COVID-19: Researchers warn of sharp rise in antimicrobial resistance – National Herald

The paper also suggests the likeliness of the gut microbiota being disrupted in severe COVID-19 patients, which may affect disease outcomes, including predisposition to secondary bacterial infections of the lung.

Jose Bengoechea, Professor of Molecular Microbiology and Director of Wellcome Wolfson Institute for Experimental Medicine at Queen's University, explains: "The lack of therapies to treat severe COVID-19 patients led clinicians to use a number of treatments to modify the activity of their immune system.

"However, it is important to note that these interventions may also increase the risk of potentially fatal secondary bacterial respiratory infections.

"Therefore, careful consideration should be given whether any potential new therapy may affect the patients' defences against bacterial infections. We believe that there is an urgent need to develop new therapeutics to treat COVID-19 targeting the virus/bacteria co-infection scenario."

The research also raises concerns about the impact of COVID-19 on antimicrobial resistance (AMR) globally.

More:

COVID-19: Researchers warn of sharp rise in antimicrobial resistance - National Herald

Novel DNA analysis will help to identify food origin and counterfeit food in the future – Science Codex

Estonian scientists are developing a DNA-based method of analysis that enables them to identify food components and specify the origin of a foodstuff.

Bioinformatics specialists at the University of Tartu, in cooperation with the Competence Centre on Health Technologies, have published a research paper in the journal Frontiers in Plant Science in which they indicated the possibility to identify components in thermally processed food using DNA analysis even if the quantities were very small. The scientists analysed thermally processed cookies that contained a small amount of lupin flour. The DNA analysis provided reliable identification of lupin even when the lupin flour content in the dough was just 0.02%.

Food always contains the DNA traces of the plants, animals and microorganisms that have been used or that the food or its raw materials have come into contact with in the production process. DNA analysis can provide valuable information on the content, origin, safety and health benefits of food and will make the identification of counterfeit foods and non-compliances in the ingredients specified on the packaging more reliable in the future. For example, certain cases gained attention last year in which the origin of honey and the authenticity of Estonian honey needed verification. The novel DNA analysis would make it possible to solve such issues.

According to Kairi Raime, the lead author of the article, Research Fellow of Bioinformatics at the Institute of Molecular and Cell Biology and a doctoral student at the University of Tartu, their method is a major step forward in the development of DNA-based methods for food analysis. "Our method helps to identify the actual biological contents and origins of food via DNA information and thus ensures the safety and authenticity of the food," she explained. Raime is planning to defend her PhD dissertation on the topic.

The DNA may be significantly degraded in processed food. Scientists extracted DNA from the cookies and analysed it using DNA sequencing technology. For the analysis of a single biscuit, approximately 20 million DNA sequences were obtained. Based on these, and by using bioinformatic analysis, it was possible to specify the DNA of the species found in the sample analysed. The main issue was the preparation of the DNA for sequencing, as the DNA is often degraded in food and even minute amounts of DNA molecules must be identified.

Kaarel Krjutkov, Head of the Precision Medicine Laboratory of the Competence Centre on Health Technologies and Senior Research Fellow of Molecular Medicine at the University of Tartu, whose laboratory was used to prepare the sequencing of the DNA extracted from the biscuits, noted that faking the DNA fingerprint of a food is complicated and expensive, and it is therefore cheaper to offer authentic food. "People can see that in medicine, precise DNA analysis is already a reality, but in food industry and in the field of food safety, the golden age of DNA-based analysis is yet to come," Krjutkov remarked.

The research used a method based on short, unique DNA sequences (k-mers) for analysing genomic DNA data, which enables the scientists to quickly identify plant or bacterial DNA present in a food or an environmental sample. The Chair of Bioinformatics at the Institute of Molecular and Cell Biology at the University of Tartu has been developing competence in the bioinformatics of k-mers and DNA analysis over the last five years. The software developed in the Chair of Bioinformatics has been used both in medicine and for providing food safety.

The article authors' earlier cooperation resulted in the NIPTIFY foetal chromosomal disorder test, which helps to detect, with almost 100% accuracy, the DNA sequences causing foetal Down syndrome in the mother's blood sample as early as the tenth week of pregnancy. The genome analysis method developed in the Chair of Bioinformatics is used to identify pathogenic bacteria, specify their disease-causing capabilities and predict antibiotic resistance. This enabled Maido Remm, Professor of Bioinformatics at the University of Tartu, and his working group to advise the management board of a production company contaminated with a dangerous strain and to help determine the spread of type ST1247 in the company during the listeria outbreak in autumn 2019.

According to Remm, the research article proves that DNA sequencing can also be used for identifying allergenic ingredients in processed food. "DNA sequencing is a promising diagnostic method which makes it possible to quickly obtain precise information about food and the microbes around us," he said. "The use of sequencing and k-mers makes it possible in a very short time to implement a diverse range of diagnostic tests that meet the needs of researchers and companies."

Read the rest here:

Novel DNA analysis will help to identify food origin and counterfeit food in the future - Science Codex

Health Workforce of the Digital Future: Techlinical Cross-products – Observer Research Foundation

object(WP_Post)#911 (24) { ["ID"]=> int(67516) ["post_author"]=> string(1) "1" ["post_date"]=> string(19) "2020-06-08 17:06:29" ["post_date_gmt"]=> string(19) "2020-06-08 11:36:29" ["post_content"]=> string(10624) "

COVID-19 has jolted the global discourse on public health into a rapid redo. To be or not to be is no longer a question or topic of debate for digital health. Embracing digital technology and data science for global health is the only way to reverse the pandemic in the short-term, and to make health systems combat-ready for the future ones.

Whether at the national or the global level, the game plan of each country will necessarily include technology-enabled defence and offence strategies to strengthen health systems. The paradigm of preparedness against future health threats will transform digital health; simultaneously, it shall also change the professional profile, skillset and toolbox of frontline health soldiers.

As governments across the world invest in expanding digital and mobile connectivity for integrating technology with health systems, an equally pressing question needs concurrent intervention. Is todays healthcare workforce prepared to deliver a digital future? The answer is a straight no on both dimensions of service preparedness, i.e., capacity and capability.

On global capacity, the total demand for health workers has always outpaced supply, with shortages varying between manageable to stark levels based on a countrys socio-economic status. With COVID-19 proving to be a brutal blow to the best-prepared health systems, health workforce capacity building has become a priority world over. An estimate by the World Health Organisation projects the global aggregate demand for 80.2 million health workers across 165 countries by 2030, whereas the current number is around 48 million.

Trained healthcare personnel, however, cannot be increased in a matter of months. It is a long-drawn process, which must begin soon enough to cover the shortage of millions of health workers. With economies slipping in a downward spiral, there is an added impetus to act quickly. It is well-established that investing in the health sector accelerates employment generation, especially for women and youth. There lies an opportunity to build the capability set of new entrants in health services based on future needs of health eco-systems. In years to come, the delivery and consumption of health will be more technology-driven than ever before. The profile of health workforce of each country must be aligned with the digital health priorities it sets for itself. While the exact construct will differ by country, the broad direction will be a combination of the principles outlined below.

For todays health workers, digitalisation of health systems and implementation of the connected care blueprint in a localised manner will shape new ways of doing their jobs. It will be in a hybrid format, comprising physical and digital care of patients in varied proportions to maximise health outcomes.

Technology integration within clinical services and products will also create new types of jobs to invent and handle public goods or medical products of future (new-age therapeutics, diagnostics and preventive health aides) using a combination of biology and computer science. They will fall at the intersection of medicine, genomics and engineering, using Artificial Intelligence (AI), Machine learning (ML), robotics, predictive analytics, and more.

It calls for urgent and parallel action by governments to kick-off upskilling and mindset rewiring of professionals in the medical and biopharma domains to adopt digital tools in their practice. The recent use case of telemedicine to deliver virtual care (force-started by COVID-19) is a glimpse into the future of model patient and physician behaviour on technology adoption. Yet, it is not fully reflective of the scale at which evolving trends in healthtech will define the speed and nature of skillset transformation for health workers in primary and tertiary care settings.

To drive the upskilling exercise, it is also critical to gauge the aptitude and willingness of todays health workers to use technology in clinical decision-making.

Pre-covid times have seen stinging debates within the medical community and health policymakers on whether technology will strip healthcare off its essential nature of being high-touch for effective patient care. Questions have been raised if AI tools will depersonalise medicine; if standard of care will dilute, or patient-centricity will be lost if AI/ML algorithms were to read radiology scans and vital signs to present clinical diagnosis or to predict disease prognosis. Legitimate doubts and ethical concerns on patients rights and data privacy have been brought forward. Most importantly, fair scepticism has been raised on safety and trustworthiness of algorithms due to inherent socio-ethnic biases and lack of situational context.

As a result, the digital health discourse has so far seen three types of participants: the Evangelists, who strongly believe that healthtech will catapult countries to meet sustainable development goals; the Cynics, who have raised many of the above questions; and the Opposers, who view technology as a threat to their careers or as an unwanted intrusion in the age-old, sacred practice of medicine.

Post covid, the narrative has stepped up considerably to gain the attention of the healthcare community around the world. The goings-on have led many Cynics and Opposers to shift their position into the solution-seeking quadrant, to coalesce into a new category of Constructive Critics. Together, the Evangelists and the Constructive Critics will form a powerful community to extract the most-balanced and effective benefits of digital and AI/ML technology in healthcare delivery, without diluting patient-centricity, data security and privacy rights. They will also be the change catalysts, who will lay down the foundation and constructs of the new system to work as inter-disciplinary teams, and to train and arm the workforce of today with digital skills.

As a long-term goal, cultivating aptitude and imparting new skills to create a digital-savvy health workforce of the future calls for considerable reform in the medical education system. This will need a redesign of curricula, training methods and skill evaluation techniques. In addition, student selection criteria and aptitude tests for clinical careers will have to be revamped.

Institutional frameworks of medical and nursing schools will have to create flexible claw-ins with technical education institutes to co-develop matrixed pedagogy programmes. For example, a medical science, nursing, or paramedical student would necessarily have to take credit courses in computer science, bio-engineering, mathematics or allied disciplines. Similarly, it will be essential for engineering and mathematics students to partake selective medical courses, to gain insights and orientation on experiences and challenges of patients and health workers in clinical settings to conceive future digital products for the healthcare and life sciences sectors. Selection and training for primary health workers will also incorporate digital literacy as an essential requirement.

Few countries such as the UK and Australia had begun deliberation on their workforce strategy to enable digital health last year. For example, in 2019, the National Health Service, UK identified genomics, telemedicine and AI-based technologies as thrust areas to plan training and education of their future workforce.

To sum-up, the future will have inter-professional teams working in collaboration to co-create and monitor learning systems behind clinical decision making digital tools. Frontrunners for these roles will be the ones with a combination skillset in technology and clinical sciences or techlinical. All health workers will be digital-savvy to deploy these tools in care settings to improve patient outcomes. The combined effect of both will increase efficiency and effectiveness of delivery at a systemic level. As predicted by digital health evangelist, Dr.Eric Topol (Professor of Molecular Medicine, Scripps Research Translational Institute), use of AI and technology-aides in medicine will create time and space to deliver real healing to the patients.

Read more here:

Health Workforce of the Digital Future: Techlinical Cross-products - Observer Research Foundation

Antibiotic-destroying genes widespread in bacteria in soil and on people – Washington University School of Medicine in St. Louis

Visit the News Hub

Chemical compound restores tetracycline's effectiveness by blocking bacterial resistance

Shown above are two different 3D views of TetX7 (green), a tetracycline-destroying enzyme that causes resistance to all tetracycline antibiotics (the small multicolored molecule in the center). Researchers at Washington University in St. Louis and the National Institutes of Health (NIH) have found that genes that confer the power to destroy tetracyclines are widespread in bacteria that live in the soil and on people.

The latest generation of tetracyclines a class of powerful, first-line antibiotics was designed to thwart the two most common ways bacteria resist such drugs. But a new study from researchers at Washington University in St. Louis and the National Institutes of Health (NIH) has found that genes representing yet another method of resistance are widespread in bacteria that live in the soil and on people. Some of these genes confer the power to destroy all tetracyclines, including the latest generation of these antibiotics.

However, the researchers have created a chemical compound that shields tetracyclines from destruction. When the chemical compound was given in combination with tetracyclines as part of the new study, the antibiotics lethal effects were restored.

The findings, available online in Communications Biology, indicate an emerging threat to one of the most widely used classes of antibiotics but also a promising way to protect against that threat.

We first found tetracycline-destroying genes five years ago in harmless environmental bacteria, and we said at the time that there was a risk the genes could get into bacteria that cause disease, leading to infections that would be very difficult to treat, said co-senior author Gautam Dantas, PhD, a professor of pathology and immunology and of molecular microbiology at Washington University School of Medicine in St. Louis. Once we started looking for these genes in clinical samples, we found them immediately. The fact that we were able to find them so rapidly tells me that these genes are more widespread than we thought. Its no longer a theoretical risk that this will be a problem in the clinic. Its already a problem.

In 2015, Dantas, also a professor of biomedical engineering, and Timothy Wencewicz, PhD, an associate professor of chemistry in Arts & Sciences at Washington University, discovered 10 different genes that each gave bacteria the ability to dice up the toxic part of the tetracycline molecule, thereby inactivating the drug. These genes code for proteins the researchers dubbed tetracycline destructases.

But they didnt know how widespread such genes were. To find out, Dantas and first author Andrew Gasparrini, PhD then a graduate student in Dantas lab screened 53 soil, 176 human stool, two animal feces, and 13 latrine samples for genes similar to the 10 theyd already found. The survey yielded 69 additional possible tetracycline-destructase genes.

Then they cloned some of the genes into E. coli bacteria that had no resistance to tetracyclines and tested whether the genetically modified bacteria survived exposure to the drugs. E. coli that had received supposed destructase genes from soil bacteria inactivated some of the tetracyclines. E. coli that had received genes from bacteria associated with people destroyed all 11 tetracyclines.

The scary thing is that one of the tetracycline destructases we found in human-associated bacteria Tet(X7) may have evolved from an ancestral destructase in soil bacteria, but it has a broader range and enhanced efficiency, said Wencewicz, who is a co-senior author on the new study. Usually theres a trade-off between how broad an enzyme is and how efficient it is. But Tet(X7) manages to be broad and efficient, and thats a potentially deadly combination.

In the first screen, the researchers had found tetracycline-destructase genes only in bacteria not known to cause disease in people. To find out whether disease-causing species also carried such genes, the scientists scanned the genetic sequences of clinical samples Dantas had collected over the years. They found Tet(X7) in a bacterium that had caused a lung infection and sent a man to intensive care in Pakistan in 2016.

Tetracyclines have been around since the 1940s. They are one of the most widely used classes of antibiotics, used for diseases ranging from pneumonia, to skin or urinary tract infections, to stomach ulcers, as well as in agriculture and aquaculture. In recent decades, mounting antibiotic resistance has driven pharmaceutical companies to spend hundreds of millions of dollars developing a new generation of tetracyclines that is impervious to the two most common resistance strategies: expelling drugs from the bacterial cell before they can do harm, and fortifying vulnerable parts of the bacterial cell.

The emergence of a third method of antibiotic resistance in disease-causing bacteria could be disastrous for public health. To better understand how Tet(X7) works, co-senior author Niraj Tolia, PhD, a senior investigator at the National Institute of Allergy and Infectious Diseases at the NIH, and co-author Hirdesh Kumar, PhD, a postdoctoral researcher in Tolias lab, solved the structure of the protein.

I established that Tet(X7) is very similar to known structures but way more active, and we dont really know why because the part that interacts with the tetracycline rings is the same, Kumar said. Im now taking a molecular dynamics approach so we can see the protein in action. If we can understand why it is so efficient, we can design even better inhibitors.

Wencewicz and colleagues previously designed a chemical compound that preserves the potency of tetracyclines by preventing destructases from chewing up the antibiotics. In the most recent study, co-author Jana L. Markley, PhD, a postdoctoral researcher in Wencewiczs lab, evaluated that inhibitor against the bacterium from the patient in Pakistan and its powerful Tet(X7) destructase. Adding the compound made the bacteria two to four times more sensitive to all three of the latest generation of tetracyclines.

Our team has a motto extending the wise words of Benjamin Franklin: In this world nothing can be said to be certain, except death, taxes and antibiotic resistance, Wencewicz said. Antibiotic resistance is going to happen. We need to get ahead of it and design inhibitors now to protect our antibiotics, because if we wait until it becomes a crisis, its too late.

Gasparrini AJ, Markley JL, Kumar H, Wang B, Fang L, Irum S, Symister C, Wallace M, Burnham CAD, Andleeb S, Tolia NH, Wencewicz TA, Dantas G. Tetracycline-inactivating enzymes from environmental, human commensal, and pathogenic bacteria cause broad-spectrum tetracycline resistance. Communications Biology. May 15, 2020. DOI: 10.1038/s42003-020-0966-5

This work is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), grant number R01 AI123394; the National Institute of General Medical Sciences, training grant number T32 GM007067; the National Institute of Diabetes and Digestive and Kidney Diseases, training grant number T32 DK077653; and Washington University, W.M. Keck Postdoctoral Program in Molecular Medicine and the Chancellors Graduate Fellowship Program.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read more:

Antibiotic-destroying genes widespread in bacteria in soil and on people - Washington University School of Medicine in St. Louis

11 Foods to Avoid With IBS – LIVESTRONG.COM

If you have irritable bowel syndrome (IBS), the foods you eat can make all the difference in how you feel. Some foods can trigger symptoms, and limiting them may mean less abdominal pain, bloating, gas and constipation.

Symptom triggers are different for everyone, but cheese and pasta may be some of the foods to avoid with IBS.

Image Credit: vadimguzhva/iStock/GettyImages

Find out which foods may be aggravating your IBS and what you can choose instead, so you can enjoy your meals with less stress.

Cow's milk and other dairy products containing lactose like yogurt, ice cream, cream cheese and cottage cheese can trigger IBS symptoms.

Lactose is a sugar that's tough to digest, according to Harvard Health Publishing, as well as a FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols). FODMAPs are short-chain carbohydrates that can cause gastrointestinal distress.

What to eat instead: Try pouring lactose-free, oat, almond or rice milk into your cereal or coffee. You can also try dairy-free yogurts and ice creams. Hard cheeses are also a better choice than soft cheeses as they contain less lactose, according to the Cleveland Clinic.

Not being able to enjoy a cup or two of coffee or tea in the morning is a tough reality for some IBS sufferers, but caffeine is a stomach irritant that can increase diarrhea, according to John Hopkins Medicine. But don't despair, sleepyheads! According to an article published June 2017 in the World Journal of Gastroenterology, caffeine may be tolerated if it's restricted to 400 milligrams.

What to drink instead: If it's still a big no for you, there are many good substitutions. "Herbal teas, things like Teeccino and Dandy Blend tea are also great they're kind of like coffee but aren't," says Isabel Smith, RD, CDN. "There are mushroom elixirs (like Four Sigmatic), and a good cup of ginger in hot water can also do the trick for energy and soothing."

3. Foods High in Fructose

Being cautious with certain fruits, drinks and processed foods containing high amounts of fructose, a FODMAP compound, can help with IBS symptoms. According to Food Intolerance Diagnostics, it's a good idea to limit the following:

Processed foods containing high-fructose corn syrup, honey, agave nectar or molasses should also be limited or avoided.

What to eat instead: Reach for cantaloupe, grapes, kiwi, oranges, pineapple, strawberries, eggplant, green beans, bok choy, carrots, cucumber, lettuce, potatoes, spinach and zucchini, which are gentler on the digestive system. Also, you should start becoming a staunch label sleuth with those processed foods!

Vegetables like cabbage, cauliflower, Brussels sprouts and broccoli are rich in vitamins and minerals and full of cancer-fighting phytonutrients. But they're also high in fructans and galactooligosaccharides, says gastroenterologist Jacqueline Wolf, MD.

"These are inadequately broken down by digestion and give gas and bloating," Dr. Wolf says.

What to eat instead: If these foods trigger symptoms for you, you can still get your fill with easier-to-digest veggies like eggplant, green beans, bok choy, carrots, cucumbers, lettuce, potatoes, spinach and zucchini. And eat up, becausenutrients!

Beans, chickpeas, lentils and soy beans are protein powerhouses and excellent sources of minerals like iron, magnesium and zinc. But they're all high in fiber and contain oligosaccharides (a FODMAP compound), according to the U.S. Dry Beans Council, which means they may cause some major bloating and gas issues.

What to eat instead: There aren't any real "replacements" for beans, but you can try soaking them in water overnight to tame gas-producing substances, according to the Cleveland Clinic. And keep in mind that you may react differently to different types of legumes, so you may want to test out your reaction before you write them out of your diet completely.

6. Sugar Alcohols (Polyols)

You may be tempted to reach for sugar-free foods if you're watching your weight, but many of these foods contain sugar alcohols (substitutes) like the polyols: sorbitol, xylitol, lactitol, mannitol, erythritol and maltitol. These FODMAPs, according to a September 2016 article in the International Journal of Dentistry, may cause gas, bloating and diarrhea, so it's probably best to limit sugarless gum and any other food labeled "sugar-free."

What to eat instead: "Eat food with real sugar in it! I can't say this enough it makes a huge difference for people, especially with IBS," Smith tells LIVESTRONG.com.

This type of fiber (roughage), promotes the movement of material through your digestive system and increases stool bulk, as it isn't broken down by the gut, according to the Mayo Clinic. This is good news for most people, but a June 2017 article in the International Journal of Molecular Medicine noted that insoluble fiber may cause diarrhea in IBS sufferers.

What to eat instead: You may want to try some foods containing soluble fiber, which may slow things down a bit. Citrus fruits, carrots and barley are good choices.

Having a glass of wine or a cocktail here and there may be OK for some, but consuming a lot of alcohol (binge drinking) can wreak havoc on your digestive system. Alcohol acts as an irritant and increases digestive juices, slowing down the digestive process, according to an article published in 2017 in Alcohol Research: Current Reviews. And findings in a study published in February 2013 in the American Journal of Gastroenterology showed that heavy alcohol intake may exacerbate gastrointestinal symptoms with IBS.

Also, pay attention to what you're ordering, Jenny Champion, RD, CPT, suggests, because it may not be the alcohol that's causing the issue. Barley in beer or the sugary or carbonated drinks mixed with the alcohol may trigger symptoms.

What to drink instead: Wine and martinis mixed with natural ingredients like mint, basil and ginger are safer options, Champion says. And remember to practice moderation.

Gluten is a protein found in many carbohydrate foods like bread, pasta, bagels and some cereals. Because they contain fructans and are high on the FODMAP list, these foods can aggravate your stomach. Granted, you could just have a gluten sensitivity, but you should definitely be checked for Celiac Disease if gluten does do a number on you.

What to eat instead: Unless you have another serious GI issue, such as celiac disease, it's not a good idea to eliminate gluten altogether, according to The Ohio State University Wexner Medical Center, since these foods provide important nutrients. Rather, try avoiding these foods for a couple weeks, then slowly reintroducing them to determine your level of intolerance.

If you do have to avoid gluten, though, there are many gluten-free options available in your grocery store and at most restaurants.

Soda, seltzer and club soda are often big contributors to IBS symptoms, particularly a bloated belly. The fizz can bubble up in your digestive tract, causing belching, bloating and gas, per the American College of Gastroenterology. And you're also hit with a double-whammy since many of these drinks have artificial sweeteners.

What to drink instead: There are plenty of ways to hydrate without the bubbles. Smith suggests tea, fruit-infused water and fresh veggie/fruit juices (that are FODMAP-compliant, of course.). Freezing bits of fruit and herbs or spices in ice cube trays to drop into a tall glass of H2O is another fun idea.

Need a way to easily track your daily water intake? Download the MyPlate app to do the job, so you can stay focused and achieve your goals!

It's hard not to indulge sometimes, but for IBS sufferers, chocolate may be a big no-no. Chocolate contains caffeine approximately 6 milligrams per ounce in milk chocolate and 23 in dark. But dark may be the safer bet, as it shouldn't contain any lactose. Unfortunately, there can be traces of milk in dark chocolate, according to the U.S. Food and Drug Administration.

What to eat instead: Those who can't have any lactose should check the advisory statement on dark chocolate packaging (like "may contain dairy" or "made on equipment shared with milk").

There are dairy-free and vegan chocolate options, but again, check the packaging and labels to make sure they don't contain any triggering ingredients.

Link:

11 Foods to Avoid With IBS - LIVESTRONG.COM